绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万股。 ...

智通财经APP讯，绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万 股。 ...

格隆汇8月20日丨绿叶制药(02186.HK)发布公告，2025年8月20日，按每股兑换价港币3.672元兑换由公 司发行的2025年到期的2500万美元5.85%利率可转换债券而发行5291.94万股普通股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 02186 ...

Core Viewpoint - Green Leaf Pharmaceutical experienced a 4.02% decline in stock price, closing at 3.82 CNY per share with a trading volume of 302 million CNY on August 20 [1] Company Overview - Green Leaf Pharmaceutical Group Limited focuses on the development, production, promotion, and sales of innovative drugs in four major therapeutic areas: oncology, central nervous system, cardiovascular system, and digestive and metabolic diseases [1] - The company has a product portfolio of over 30 products, distributed across more than 80 countries and regions globally [1] Operational Highlights - In 2021, the company's product sales reached all 30 provinces, autonomous regions, and municipalities in China, supported by approximately 1,000 sales and marketing personnel and a network of about 1,780 distributors [1] - The products are sold to over 19,330 hospitals, with international market coverage extending to 80 countries or regions [1] Financial Performance - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]

Core Viewpoint - The company, Green Leaf Pharmaceutical (02186.HK), is set to hold a board meeting on August 28, 2025, to approve its mid-term performance for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, if applicable [1] Related Events - Green Leaf Pharmaceutical plans to hold a board meeting on August 28 to approve mid-term performance [1] - The company has completed patient enrollment for the Phase III clinical trial of Ruxolitinib for the treatment of generalized anxiety disorder in China [1]

綠葉製藥集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 主 席 劉殿波 香 港，二 零 二 五 年 八 月 十 八 日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 殿 波 先 生、楊 榮 兵 先 生、袁 會 先 先 生 及 祝 媛 媛 女 士；本 公 司 非 執 行 董 事 為 宋 瑞 霖 先 生 及 黃 立 明 先 生；及 本 公 司 獨 立 非 執 行 董 事 為 張 化 橋 先 生、盧 毓 琳 教 授、梁 民 傑 先 生、蔡 思 聰 先 生 及 夏 蓮 女 士。 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 董事會會議通告 綠葉製藥集團有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零二五年八月二十八日（星 期 四）舉 ...

Group 1 - The core viewpoint of the article highlights the performance and market presence of Green Leaf Pharmaceutical, which saw a stock price increase of 2.89% to 3.91 HKD per share with a trading volume of 302 million HKD on August 18 [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, focusing on the development, production, promotion, and sales of innovative drugs [1] - The company has a diverse product portfolio with over 30 products, and its sales network includes approximately 1,000 sales and marketing personnel and around 1,780 distributors, reaching over 19,330 hospitals in China and covering more than 80 countries and regions internationally [1] Group 2 - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]

Group 1 - The core point of the news is that Green Leaf Pharmaceutical has completed patient enrollment for the Phase III clinical trial of its innovative drug, Ruoxinlin, aimed at treating generalized anxiety disorder (GAD) [1] - The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study involving 555 patients, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) scores at the end of week 8 [1] - The company expects to complete the clinical trial by the end of this year and submit a marketing application for this indication [1] Group 2 - Generalized anxiety disorder is the most common mental disorder in China, affecting approximately 53.1 million people as of 2021 [1] - There have been no innovative drugs approved for the treatment of anxiety disorders globally in the past 15 years, making Ruoxinlin a potential first-in-class serotonin, norepinephrine, and dopamine reuptake inhibitor (SNDRI) for GAD [1] Group 3 - Ruoxinlin is the first independently developed innovative drug in China for treating depression, having been approved in 2022, and has shown significant clinical efficacy and safety [3] - The drug has been recognized for its ability to improve depressive symptoms without causing insomnia, sedation, or affecting sexual function, weight, and lipid metabolism [3] - Ruoxinlin has served over 80,000 patients since its launch and is the fastest-growing antidepressant in China [3] Group 4 - The demand for treatments in the central nervous system field, including depression and anxiety, is substantial, but new drug development has been relatively slow [4] - The company has received approvals for a series of competitive innovative drugs in various markets, including the US, Europe, and Japan [4] - The company is actively developing next-generation innovative drugs, with several first-class innovative drugs in clinical stages targeting multiple receptors [4]

Group 1 - The core point of the news is that Green Leaf Pharmaceutical (02186.HK) has completed patient enrollment for its Phase III clinical trial of the innovative drug Ruoxinlin® (Toralacitinib) for treating Generalized Anxiety Disorder (GAD) [1] - The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study involving 555 patients, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) scores from baseline at week 8 [1] - The company expects to complete the clinical trial by the end of this year and submit a marketing application for this indication [1] Group 2 - Generalized Anxiety Disorder is the most common mental disorder in China, affecting approximately 53.1 million people as of 2021, with a long duration and high recurrence rate impacting patients' quality of life [1] - Ruoxinlin® is expected to be the first drug globally approved for treating GAD that acts as a triple reuptake inhibitor of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) [1] - Current first-line treatments for GAD include SSRIs and SNRIs, which have common side effects leading to low patient compliance and treatment discontinuation [2] Group 3 - Ruoxinlin® is the first domestically developed innovative drug for treating depression in China, having been approved for market since 2022, and has shown efficacy and safety in clinical settings [2] - Clinical trials have demonstrated that Ruoxinlin® significantly improves depression symptoms without causing insomnia, sedation, or affecting sexual function, weight, and lipid metabolism [2] - The drug also shows potential anxiolytic effects, improving HAM-A scores and other anxiety-related measures while providing antidepressant benefits [2]